欧美日本一道本一区二区_亚洲免费影视_91手机在线看片_精品欧美成人高清在线观看_少妇作爱bbbb免费看_51久久夜色精品国产水果派解说

印度 Lupin 魯賓
魯賓有限公司是一家以創(chuàng)新為主導(dǎo)，在世界范圍內(nèi)為發(fā)達(dá)國家和發(fā)展中國家提供廣泛的高品質(zhì)，低價(jià)位的仿制及品牌制劑和原料藥的跨國公司。
在魯賓，我們努力通過在世界范圍內(nèi)為患者提供可負(fù)擔(dān)、可獲得的藥品，為人們營造健康的生活。我們致力于發(fā)現(xiàn)、研發(fā)和使創(chuàng)新藥物商業(yè)化來滿足未能被滿足的醫(yī)療需求。
當(dāng)成為世界上最大的結(jié)核藥生產(chǎn)商時(shí)，魯賓首次得到了認(rèn)可。多年來，公司已提升了價(jià)值鏈，不僅在中間體和原料藥方面有所建樹，也充分利用其優(yōu)勢在全球范圍內(nèi)建立起制劑業(yè)務(wù)，足跡遍布美國、印度、日本、澳大利亞、英國、德國、獨(dú)聯(lián)體等。

我們的優(yōu)勢：

完全綜合性制藥公司
??在仿制藥、新化學(xué)實(shí)體、新型給藥系統(tǒng)、新生物實(shí)體、研究等領(lǐng)域建立了強(qiáng)大的科研基地
??獲得國際管理機(jī)構(gòu)批準(zhǔn)的世界級的GMP標(biāo)準(zhǔn)生產(chǎn)設(shè)施，包括美國，
??以堅(jiān)實(shí)的科技和專業(yè)知識為依托，提高產(chǎn)品科技含量，生產(chǎn)出更具創(chuàng)新性的產(chǎn)品
??強(qiáng)有力的全球足跡：美國、印度、日本、澳大利亞、英國、德國、獨(dú)聯(lián)體等
??大型動態(tài)營銷隊(duì)伍和?強(qiáng)大的分銷網(wǎng)絡(luò)

Lupin是由擁有化學(xué)碩士學(xué)位的億萬富翁、董事長Desh Bandhu Gupta于1968年一手創(chuàng)辦。根據(jù)其2011年度報(bào)告,Lupin在國內(nèi)市場擁有大約4000名醫(yī)療銷售代表。Gupta及其家族控制了該公司46.96%的股份。

?
Headquartered in Mumbai, India, Lupin Limited today is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world.

Dr. Desh Bandhu Gupta's vision and dream to fight life threatening infectious diseases and to manufacture drugs of the highest social priority led to the formation of Lupin in the year 1968. His Vision, his inimitable commitment and verve have steered Lupin to achieving the distinction of becoming one of the fastest growing Generic pharmaceutical companies globally.

Lupin first gained recognition when it became one of the world's largest manufacturers of Tuberculosis drugs. The Company today has significant market share in key markets in the Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy segments, not to mention global leadership positions in the Anti-TB and Cephalosporins segments. The Company's R&D endeavours have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals. Lupin's world class manufacturing facilities, spread across India and Japan, have played a critical role in enabling the companies realize its global aspirations. Benchmarked to International standards, these facilities are approved by international regulatory agencies like US FDA, UK MHRA, Japan's MHLW, TGA Australia, WHO, and the MCC South Africa.

Our Drugs and products reach over 70 countries in the world. Today, Lupin has emerged as the 5th largest and the fastest growing Top 5 company in the U.S (by prescriptions), the only Asian company to achieve that distinction. The company is also the fastest growing, top 5 pharmaceutical players in India (ORG IMS) and the fastest growing top 10 Generic players in Japan and South Africa. (IMS), Today, Lupin also has the unique distinction of being the fastest growing top 10 Generics players in the two largest pharmaceutical markets of the world – The U.S (ranked 5th by prescriptions & growing at 52 %) and Japan (ranked 7th and growing at 23%). Lupin's Consolidated Revenues and Profit after Tax were Rs. 57,068 million and Rs. 8,626 million for FY 2010-11.

Going forward, our research backbone, best-in-class class manufacturing capabilities, marketing and servicing depth globally will stand us in good stead. The company will continue to focus on identifying and developing niche segments, a differentiated product portfolio in all its chosen markets backed up by strategic partnerships and in-licensing, and investment in new areas such as biosimilars - well on-course to becoming a global pharmaceutical powerhouse.